Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa by Bionghi, N. et al.
RESEARCH ARTICLE Open Access
Pilot evaluation of a second-generation
electronic pill box for adherence to
Bedaquiline and antiretroviral therapy in
drug-resistant TB/HIV co-infected patients
in KwaZulu-Natal, South Africa
N. Bionghi1,2, A. Daftary2,5, B. Maharaj2, Z. Msibi2, K. R. Amico6, G. Friedland7, C. Orrell8, N. Padayatchi2
and M. R. O’Donnell2,3,4*
Abstract
Background: The introduction of Bedaquiline, the first new antimycobacterial drug in over 40 years, has
highlighted the critical importance of medication adherence in drug-resistant tuberculosis (DR-TB) treatment to
prevent amplified drug-resistance and derive sustained benefit. Real-time electronic dose monitoring (EDM)
accurately measures adherence and allows for titration of adherence support for anti-retroviral therapy (ART). The
goal of this study was to evaluate the accuracy and acceptability of a next-generation electronic pillbox (Wisepill
RT2000) for Bedaquiline-containing TB regimens.
Methods: Eligible patients were DR-TB/HIV co-infected adults hospitalized for the initiation of Bedaquiline-
containing treatment regimens in KwaZulu-Natal, South Africa. A one-way crossover design was used to evaluate
levels of adherence and patient acceptance of EDM. Each patient was given a Wisepill device which was filled with
ART, Levofloxacin or Bedaquiline over three consecutive weeks. Medication adherence was measured using Wisepill
counts, patient-reported seven-day recall, and weekly pill count. An open-ended qualitative questionnaire at the
end of the study evaluated participant acceptability of the Wisepill device.
Results: We enrolled 21 DR-TB/HIV co-infected inpatients admitted for the initiation of Bedaquiline from August
through September 2016. In aggregate patients were similarly adherent to Bedaquiline (100%) compared to
Levofloxacin (100%) and ART (98.9%) by pill count. Wisepill was more sensitive (100%) compared to seven-day recall
(0%) in detecting non-adherence events (p = 0.02). Patients reported positive experiences with Wisepill and
expressed willingness to use the device during a full course of DR-TB treatment. There were no concerns about
stigma, confidentiality, or remote monitoring.
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Conclusion: In this pilot study patients were highly adherent to Bedaquiline by all adherence measures. However,
there was lower adherence to ART by pill count and Wisepill suggesting a possible challenge for adherence with
ART. The use of EDM identified significantly more missed doses than seven-day recall. Wisepill was highly
acceptable to DR-TB/HIV patients in South Africa, and is a promising modality to support and monitor medication
adherence in complex treatment regimens.
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Background
Tuberculosis (TB) is the leading cause of death globally
from a single infectious pathogen having surpassed HIV
in estimated mortality in 2015 [1]. The emergence and
propagation of drug-resistant TB (DR-TB), with an esti-
mated 580,000 new cases in 2015, has led to a marked in-
crease in the number of tuberculosis patients requiring
more extensive and complex treatment regimens [2]. Des-
pite the large number of drugs utilized in the management
and treatment of DR-TB, current treatments continue to
be ineffective in operational settings: success rates range
from 48% for MDR-TB to 22% in patients with XDR-TB
[3]. Outcomes are often worse for TB patients co-infected
with HIV. This has significant implications for manage-
ment of DR-TB in regions of South Africa such as
KwaZulu-Natal, where the majority of DR-TB patients are
HIV co-infected [4, 5].
Medication adherence is associated with TB culture con-
version in DR-TB/HIV treatment but the full impact of
non-adherence and lack of retention in care on treatment
outcome is not well understood. Based on biologic under-
standing and modeling exercises, poor adherence is thought
to drive the development of drug resistance in the treatment
of Mycobacterium tuberculosis (MTB) [6–8]. While consid-
erable attention to measurement of adherence to HIV anti-
retroviral therapy (i.e. self-report, pill count, pharmacy
refills, and electronic monitoring) has produced a robust lit-
erature and evidence base, similar work with EDM pillboxes
has not been done in TB and TB/HIV co-infection treat-
ment [9, 10]. Real-time monitoring of adherence using a
next-generation electronic pillbox (Wisepill) has important
potential to identify early adherence lapses prior to TB
treatment failure and may have a role to play in the preven-
tion of drug resistance [11]. In addition, electronic adher-
ence monitoring may be beneficial when incorporated
within a patient-centered model of improving adherence,
that contextualizes missed doses within the clinical, socio-
economic, and structural factors surrounding this highly
stigmatized group [12].
Bedaquiline is the first new drug licensed for the treat-
ment of DR-TB in over 40 years (Janssen Therapeutics,
2015). In clinical trials Bedaquiline-containing regimens
showed an increase rate of 21% TB culture conversion
compared with control regimens but MTB resistance to
Bedaquiline in the presence of suboptimal drug-levels has
already been described [13, 14]. Bedaquiline is dosed inter-
mittently (e.g. three times weekly) and has a long half-life
rendering it vulnerable to emergent drug-resistance when
medication adherence is sub-optimal. Currently, there are
no studies on measurement or improvement of adherence
to Bedaquiline in DR-TB/HIV treatment.
We designed this mixed-methods pilot study as pre-
liminary data for a larger study of adherence in DR-TB
HIV in South Africa (PRAXIS, NIH R01AI124413). The
goals were to measure self-administered medication ad-
herence to Bedaquiline compared to other second-line
TB medications and ART in South African patients with
DR-TB/HIV coinfection and to assess patient acceptance
of a next-generation electronic pill box.
Methods
Study site and population
This pilot study was conducted at a TB referral hospital in
KwaZulu-Natal, South Africa from September through
October 2016. Eligible participants were adults (> age 18)
with drug-resistant TB/HIV co-infection on ART who were
referred for the initiation of a Bedaquiline-containing treat-
ment regimen. Capacity to give written informed consent
in either English or isiZulu was required for enrollment.
Participant age, gender, previous TB history, and previous
MDR-TB history were obtained by a Zulu-speaking staff
member at enrollment in the study and other data was ab-
stracted from the clinical chart.
Study design
This study used a mixed methods approach with a pro-
spective one-way crossover design and qualitative patient
questionnaires (Fig. 1). On enrollment participants were
provided with a Wisepill RT2000 device and instructed
on its use. A single type of medication was stored in the
Wisepill device at a time to reduce confounding and for
practical space reasons. The Wisepill device was sequen-
tially loaded first with ART (either Nevirapine or Lopi-
navir/Ritonavir, twice daily dosing), then Levofloxacin
(twice daily dosing), and lastly Bedaquiline (3 doses per
week), each with a one week supply of medication
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reflecting the dosing. For each week, the patients took
the designated medication exclusively from the Wisepill
device, without supervision from hospital staff. Other
medications in the patients’ treatment regimens were ad-
ministered by a nurse per the hospital protocols, and
nurses were informed that Wisepill medications would
be taken by the patients independently. At the end of
the week a pill count was performed only for the medi-
cation in the Wisepill device, self-reported adherence for
the medication in the Wisepill device was recorded
based on a brief patient interview, and the next medica-
tion was loaded; the process repeated until all three
medications were assessed. At the end of the study all
patients had a questionnaire administered to elicit
opinions about the feasibility and effectiveness of the
Wisepill device. During treatment, routine monitoring
including electrolytes and electrocardiogram was per-
formed as per the treating clinician.
Wisepill adherence monitoring device
The Wisepill RT2000 3G (‘Wisepill’) device has dimensions
of 30 × 60 × 130 mm and includes a seven-compartment in-
sert. It is powered by a 3.7 V lithium polymer rechargeable
battery and utilizes a Subscriber Identity Module (SIM) card
and GSM cellular telephone network. Each time the device
is opened, a cellular signal is transmitted to and recorded
on an internet server based in Cape Town, South Africa
(Fig. 2). Research staff can access this data immediately by
signing into the secure Wisepill Web Server (Fig. 3). In the
case of device power failure or signal transmission malfunc-
tion, the Wisepill device is capable of storing data for later
transmission when connectivity is re-established. As part of
this study the SMS messaging functionality was not used.
Adherence data and measures
Adherence was measured via three methods: self-
reported, weekly pill count, and Wisepill data. A
* Nevirapine or Lopinavir/Ritonavir
Patient consent
Patient education 
ART* (twice 
daily, 14 pills 
total) loaded in 
Wisepill device
ART self-reported 
adherence and pill 
count collected 
(end of week 1)
Levofloxacin 
(twice daily, 14 
pills total) loaded 
in Wisepill device
Levofloxacin self-
reported 
adherence and pill 
count collected 
(end of week 2)
Bedaquiline (thrice 
weekly, 3 pills total) 
loaded into Wisepill 
device
Bedaquiline self-
reported adherence 
and pill count 
collected (end of 
week 3)
Patient end of study 
questionnaire
Week 1 Week 2 Week 3
Fig. 1 Study design
Fig. 2 Wisepill device functions. The Wisepill device transmits a wireless signal to the Wisepill web server when device is opened. Device openings are
recorded in real-time on the online dashboard and available for users to view. If the SMS reminder service is used, the patients/caregivers may receive
message reminders when a medication dose is due or overdue. Image obtained from Wisepill Technologies with permission
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staff member not affiliated with the treatment team
obtained patient self-reported adherence at the end
of each week by asking in the patient’s language:
“How many doses of the medication did you miss?”
Weekly pill count was ascertained at the end of each
week of medication by counting the number of pills
remaining in the pillbox before loading the next
week of pills. Wisepill data was collected continu-
ously over the three weeks and downloaded from the
online Wisepill Web Server at the end of the study.
Adherence was determined utilizing the following
formula for each week of medication: (number of
doses taken)/(number of prescribed doses). Adher-
ence levels were determined and compared for all
three measures.
Acceptability and feasibility of the Wisepill device
A structured, open-ended qualitative questionnaire
was administered by an isiZulu-speaking staff mem-
ber on the last day of the three-week study period to
document participant perspectives and determine
feasibility and acceptability of the Wisepill device.
Questions investigated the participants’ experiences
with and views on using the device and real-time
monitoring, preferences regarding medication in the
pillbox, ease or difficulty of use, storage of the de-
vice, potential challenges with stigma while using the
device, and recommendations for improvement.
Data analysis
Descriptive statistics including medians, interquartile
ranges, and frequencies were calculated. Correlations
of measures of adherence were calculated using
paired sample t-tests and tests of significance were
performed using Fisher’s exact tests (SPSS Version
24). Sensitivity and specificity were calculated using
standard methods and confidence intervals were cal-
culated using Clopper-Pearson methods. Data from
the open-ended study questionnaires was translated
into English, checked for accuracy, and subjected to
qualitative content analysis [15].
Results
Participants
There were 21 inpatients enrolled in the pilot study
(Table 1). The participants were TB/HIV co-infected pa-
tients on anti-retroviral therapy (either Nevirapine or
Lopinavir/Ritonavir, both twice daily dosing) and a TB
treatment regimen that included Levofloxacin (once
daily) and Bedaquiline (three times weekly). The median
age of the participants was 42 years (IQR 33.5–54); 12 of
the 21 were men, and 6 (29%) reported previously being
diagnosed with TB. Six patients with a history of TB re-
ported having completed their prior treatments. Only
one patient reported having a previous episode of MDR-
TB. One patient exited the study after completing the
week of ART.
Intake day
In
ta
ke
 t
im
e 
NVP or 
Aluvia*
Levofloxacin 
500mg QD
Bedaquiline
300mg TIW
Fig. 3 Example of participant intakes reported on Wisepill online dashboard. Example online dashboard display of device openings for a single
participant during the three-week study period. The first day of the next medication week is shown with a dotted line. Medication dosing was
self-administered. Blue diamonds indicate extra Wisepill device openings for weekly pill count or reloading medications. Red circles indicate a
missed expected Wisepill device opening. *Nevirapine (NVP): 200 mg BID; Aluvia: Lopinavir 200 mg – 50 mg Ritonavir BID
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Adherence measures
For the 21 patients, there were 489 possible adherence
events (i.e. total expected doses of medication in the
time period to achieve perfect adherence). Pill count de-
tected 3 missed doses total among the patients. Using
pill count as the standard, patient-reported seven-day re-
call detected 0/3 missed doses detected by pill count
whereas the Wisepill device identified all missed doses
(3/3), with a significant difference between self-reported
and Wisepill measures of ART adherence (p = 0.02). All
3 missed doses occurred with ART. There were no non-
adherence events reported by pill count for Levofloxacin
or Bedaquiline. The difference between pill count adher-
ence for ART and anti-TB medications was not statisti-
cally significant (p = 0.602).
Utilizing pill count as the standard measure of adher-
ence, the Wisepill device had a sensitivity of 100% (95%
CI: 29.2–100%) and a specificity of 98.8% (97.3–99.6%).
Interviewer-acquired self-report of doses missed over
the past week as a measure of non-adherence had a sen-
sitivity of 0% (0–70.8%) and a specificity of 100% (99.2–
100%) (Table 2).
The Wisepill device also reported a greater number of
missed doses (represented by the number of times the de-
vice was opened) than was identified by pill count: 9
missed doses (1.8%) of the 489 total expected doses, with
three of these doses reflecting missed doses captured by
pill count as well. Eight of the missed doses were identi-
fied during the week of ART and one of these missed
doses was noted during the week of Levofloxacin. There
were no non-adherence events reported with Bedaquiline
using any method of measuring adherence, the highest ad-
herence among the three medications in this study.
Acceptability and feasibility for electronic device (Table 3)
All participants of the pilot study reported they had a posi-
tive experience using the electronic device over three weeks.
Participants felt the device had helped them to organize
their medications, and to keep their medications safe.
It stores my medication nicely, and I can have my
medication nicely packed so that not everyone can
have access to it.
Acceptability toward the Wisepill device was strongly
facilitated by its ease of use. The majority of participants
encountered no difficulties removing the medications
from the device every day. However, a small number of
participants with stiff joints experienced some difficulty
opening the device and one participant required an extra
demonstration to master handling the device.
Remote monitoring
Participants understood that they were being remotely
monitored by the electronic device, and most had no
issue with this monitoring. Many of them viewed Wise-
pill as an indication that the health care workers/health
system cared about their health and treatment success,
as reflected in the following quotes.
It made me feel very important to have people
worried about how I take my medication.
I had no problem with [monitoring], it’s like driving
on a road where there are traffic cops, I understand
that they are there to control and to make sure that
people are safe on our roads.
This form of monitoring encouraged them to take
their medications at the prescribed times, as explained
by one patient:
I do not have a problem because I am a person who
can take medication without supervision. But being
Table 2 Performance of adherence measures detecting
missed doses: Wisepill versus seven-day recall, pill count as
standard. (N = 21)*
Self-reported adherence Wisepill adherence
Sensitivity (95% CI) 0% (0–70.8%) 100% (29.2–100%)
Specificity 100% (99.2–100%) 98.8% (97.3–99.6%)
*21 patients with 489 possible adherence events. For Wisepill: 3 true positives,
6 false positives, 0 false negatives, 480 true negatives. For self-report: 0 true
positives, 0 false positives, 3 false negatives, 486 true negatives
Table 1 Participant characteristics
Characteristics Participants
N 21
Median age, years (IQR) 42 (33.5–54)
Gender, n (%)
Male 12 (57)
Female 9 (43)
HIV status, n (%)
Positive 21 (100)
ARV, n (%)
Yes 21 (100)
Previous TB, n (%)
Yes 6 (29)
No 13 (62)
Not known 2 (9)
Previous MDR-TB, n (%)
Yes 1 (5)
No 18 (86)
Not known 2 (9)
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monitored also motivated me to make sure that I take
medication.
However, a few participants were worried about failing
to adhere to the specified dosing time: “if you miss the
correct time you become very scared.”
Public use
Participants were asked about how their use of the de-
vice may be perceived by others around them. No par-
ticipant felt the device would invite stigma or a loss of
confidentiality about their HIV or TB status. Indeed,
several patients believed the device helped to maintain
their confidentiality.
Yes I would love to use [the device] especially because
people undermine and discriminate you when you are
on ARVs, so the device is very helpful because nobody
can see what is inside.
Most participants also believed that their fellow patients
“liked” or “wished they were also given” an electronic de-
vice, and nearly all of them were confident that their fam-
ily and friends – even if inquisitive – would accept them
using this device when they were discharged home.
A few participants acknowledged that the device was
likely to cause some curiosity at home, particularly be-
cause of the flashing light, and were concerned if it were
to be discovered and used by their children, or altogether
misplaced during travel.
Preferences
We asked participants about their personal preferences
for Wisepill medications. Most indicated that Wisepill
was easiest and most convenient for ARVs because they
were already accustomed to taking these medications in-
dependently, without a nurse’s supervision.
I enjoyed using [Wisepill] more when ARVs were loaded
because they are the only of medications I take at my own
time. Unlike other meds which I must take together with
what is going to be administered by the nurse.
Among the anti-TB drugs, patients preferred to pack
Bedaquiline into the Wisepill device, because they felt it
was conducive to the drug’s unique thrice weekly dosing;
all other medications were taken daily. Time in the study
was also a factor; several patients felt the longer they used
it, the more comfortable they became using the device.
When participants were probed about their sugges-
tions for future use, many of them requested increasing
the size of the device to hold more medications. Other
popular suggestions included adding an alarm reminder
for taking medication. One participant suggested such
devices should be reserved for “dedicated people, not
people who will open it and throw away the tablets.”
Discussion
This pilot study of medication adherence in DR-TB/HIV
co-infected patients demonstrates that use of real-time
electronic adherence monitoring is effective in capturing
non-adherence events and is highly acceptable to patients.
In this study, the Wisepill RT2000 device provided real-
Table 3 Wisepill acceptability and experiences: themes
identified from end-of-study questionnaire on device use and
adherence monitoring
N = 20* Percent**
Ease of using Wisepill
Easy to use 19 95%
Not easy to use 1 5%
Prefer to use Wisepill for medications 19 95%
Medication(s) easiest to take with Wisepill
ART 14 70%
Levofloxacin 2 10%
Bedaquiline 10 50%
Challenges of using Wisepill
Difficulty opening the box 3 15%
Required extra demonstration of how to use device 1 5%
Worry that children will find/use the device 2 10%
Fear of missing a dose 1 5%
Worry about losing the box during travel 1 5%
Disconcerted by the flashing light 1 5%
Loss of confidentiality regarding disease status 0 0%
Benefits of using Wisepill
Maintains confidentiality regarding disease status 6 30%
Keeps medications safe 9 45%
Keeps medications organized 3 15%
Perception of being monitored
Motivates to take medications 9 45%
Induces sense of being cared for 7 35%
Popularity of Wisepill device
Fellow patients liked the device 11 55%
Fellow patients disliked the loss of autonomy 1 5%
Fellow patients fear repercussions of missing dose 1 5%
Family would react positively to the device 18 90%
Family would be curious about the device 1 5%
Recommendations
Increase size of pillbox to accommodate more
medications
10 50%
Alarm/reminder to take medications 5 25%
Device should have a color 1 5%
Device should only be given to dedicated people 1 5%
*20 of the 21 enrolled patients completed an end-of-study questionnaire
**Patients expressed multiple views; percent reflects (number of patients)/
(total number of patients) for each statement independently
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time feedback on adherence to the online server that was
highly correlated with pill count and superior to self-
report at capturing non-adherence events when using pill
count as a reference standard. Given that Wisepill mea-
sures suggested a greater number of missed doses than
self-report as well as pill count, electronic adherence mon-
itoring may capture more non-adherence events and its
superiority and efficacy to measure adherence and guide
adherence support interventions for DR-TB/HIV treat-
ment should be evaluated in future studies.
Electronic device monitoring was able to capture ad-
herence data equally for Bedaquiline, Levofloxacin, and
ART suggesting that it is capable of effective monitoring
for TB medications as well as the HIV medications, for
which electronic adherence monitoring has been previ-
ously studied [16–20]. In this study, there were more
non-adherence events reported by pill count for ART
than for Bedaquiline (not statistically significant), con-
trary to a preceding study indicating that patients are
less likely to adhere to DR-TB treatments compared to
ART [21]. This may be because patients in this study
were recently switched from Efavirenz, a well-tolerated,
once-daily anti-retroviral drug to Nevirapine, a less tol-
erated, twice-daily drug in order to initiate Bedaquiline
therapy. High adherence to Bedaquiline may also reflect
better tolerance to Bedaquiline as compared to older
second-line TB medications.
The use of an electronic device for dispensing HIV or
DR-TB medications was a positive experience for all pa-
tients in this study and there were few technical issues
reported. Several studies of HIV treatment have demon-
strated the acceptability of Wisepill devices; in support
of the current literature, this pilot study shows that
monitoring was not a concern for patients and this level
of supervision was viewed as a sign of caring or a means
of motivation [17–19]. Participants in this study felt that
keeping the pills in an unmarked electronic device pro-
tected confidentiality and reduced the potential for
stigma. This suggests that the use of Wisepill might be
more acceptable and perhaps even preferable when pa-
tients are concerned about the stigma of their diagnosis.
This study did not explore the use of adherence re-
minder messages, but given that several participants felt
an adherence reminder function may be useful, this
function should be evaluated in future studies. In gen-
eral, patients expressed a willingness to use the device
during a full course of DR-TB treatment, which has yet
to be studied on a larger scale.
This study was limited by the short duration of follow-
up on the patients and potential biases introduced by
the order of medications by week. The temporal bias
may have affected adherence to ART (the first week) as
compared to other medications, though this is less con-
cerning given the high acceptability and ease of use
regardless of medication reported in qualitative assess-
ment. In addition, the small sample size and hospital in-
patient monitoring may limit generalizability to the
outpatient setting. Other limitations include incomplete
qualitative assessment and possible confounding due to
unmeasured variables, such as education. For this pilot
study, qualitative data was limited to descriptive content
analysis; contextual factors such as education and role of
the clinic environment were not fully explored. We plan
to address these limitations in a future larger study
(PRAXIS, NIH R01AI124413).
There are a variety of electronic health devices used in
studies for adherence monitoring. The Wisepill RT2000
device used in this study is one of several Wisepill devices
available. The Wisepill evriMED500 and evriMED1000
are table top dispensers with USB only or 2G network ac-
cess to data, respectively. They are also loaded with 5–10
different medications at a time. The characteristics and
goals of this pilot study supported the use of the Wisepill
RT2000 device for evaluation of adherence of one medica-
tion at a time with a smaller device.
Electronic health interventions, including mobile health,
have been used in supporting TB treatment adherence with
mixed results. In the largest randomized controlled trial to
date (N = 4173), comparison of 4 study arms (1 control, 3
intervention) showed that the use of text messages as re-
minders for TB medication adherence was not effective in
decreasing missed doses (p = 0.649), but electronic medica-
tion packaging (with recorded pillbox openings) succeeded
in improving TB medication adherence (p = 0.008) [22].
Next-generation cloud-based electronic monitoring devices
that transmit pill box openings in real-time, on the other
hand, have not been used in TB treatment adherence sup-
port. In HIV treatment, next-generation electronic pillboxes
for adherence monitoring have been used in low and
middle-income settings. A study in the U.S. reports similar
adherence to HIVART when using an electronic adherence
device or self-report to measure adherence [19]. On the
other hand, in a randomized control trial in Botswana, elec-
tronic adherence monitoring devices for HIVART recorded
lower adherence rates than self-report and were also shown
to be feasible in a low-income setting [20]. Similar results
were seen in a rural African setting using a Wisepill device,
where high acceptability of the device was also noted [18].
This study contributes to the current knowledge base by
applying the use of a Wisepill device to DR-TB drug regi-
mens in HIV/AIDS co-infected patients.
The results of this pilot study are encouraging for the
use of electronic monitoring adherence in DR-TB/HIV
drug regimens. These results will inform a larger study on
the effect of electronic monitoring on adherence, feasibil-
ity, and acceptability of this device for second-line TB
medications. With increasing use of Bedaquiline for the
treatment of DR-TB, further studies on adherence to TB
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regimens will be required and essential for protecting the
efficacy of this new and long-awaited drug.
Conclusions
The Wisepill device shows promise in providing real-
time adherence information in a way that is effective
and acceptable to the patient. It has the potential to
identify lapses in adherence and possibly improve ad-
herence with real-time intervention before these
lapses can lead to a negative impact on treatment
success. Self-report and pill count depend on patients
continuing to attend clinic visits, do not provide data
on potential non-adherence in real-time, may be
inferior to Wisepill in capturing non-adherence (self-
report), and may not provide the reported confidenti-
ality of the Wisepill device. Thus, the use of
electronic monitoring devices appears to be applicable
to DR-TB treatment in addition to ART, and may
have significant advantages to other commonly uti-
lized adherence monitoring methods.
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